266 related articles for article (PubMed ID: 11543729)
1. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.
Stuart JD; Lee FW; Simpson Noel D; Kadwell SH; Overton LK; Hoffman CR; Kost TA; Tippin TK; Yeager RL; Batchelor KW; Bramson HN
Biochem Pharmacol; 2001 Oct; 62(7):933-42. PubMed ID: 11543729
[TBL] [Abstract][Full Text] [Related]
2. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
[TBL] [Abstract][Full Text] [Related]
3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism.
Moss ML; Kuzmic P; Stuart JD; Tian G; Peranteau AG; Frye SV; Kadwell SH; Kost TA; Overton LK; Patel IR
Biochemistry; 1996 Mar; 35(11):3457-64. PubMed ID: 8639496
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of rat alpha-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition.
Azzolina B; Ellsworth K; Andersson S; Geissler W; Bull HG; Harris GS
J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):55-64. PubMed ID: 9328210
[TBL] [Abstract][Full Text] [Related]
7. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.
Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU
J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry.
Upreti R; Naredo G; Faqehi AM; Hughes KA; Stewart LH; Walker BR; Homer NZ; Andrew R
Talanta; 2015 Jan; 131():728-35. PubMed ID: 25281165
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies.
Tian G; Mook RA; Moss ML; Frye SV
Biochemistry; 1995 Oct; 34(41):13453-9. PubMed ID: 7577933
[TBL] [Abstract][Full Text] [Related]
10. Linear relationships between the ligand binding energy and the activation energy of time-dependent inhibition of steroid 5alpha-reductase by delta 1-4-azasteroids.
Tian G; Haffner CD
J Biol Chem; 2001 Jun; 276(24):21359-64. PubMed ID: 11279132
[TBL] [Abstract][Full Text] [Related]
11. Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors.
Olsson Gisleskog P; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Eur J Pharm Sci; 1999 Aug; 8(4):291-9. PubMed ID: 10425379
[TBL] [Abstract][Full Text] [Related]
12. Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor.
Thigpen AE; Russell DW
J Biol Chem; 1992 Apr; 267(12):8577-83. PubMed ID: 1314830
[TBL] [Abstract][Full Text] [Related]
13. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
14. 17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1.
Tian G; Stuart JD; Moss ML; Domanico PL; Bramson HN; Patel IR; Kadwell SH; Overton LK; Kost TA; Mook RA
Biochemistry; 1994 Mar; 33(8):2291-6. PubMed ID: 8117686
[TBL] [Abstract][Full Text] [Related]
15. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.
Bramson HN; Hermann D; Batchelor KW; Lee FW; James MK; Frye SV
J Pharmacol Exp Ther; 1997 Sep; 282(3):1496-502. PubMed ID: 9316864
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
[TBL] [Abstract][Full Text] [Related]
18. Effect of a novel steroid (PM-9) on the inhibition of 5alpha-reductase present in Penicillium crustosum broths.
Flores E; Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E
Steroids; 2003 Mar; 68(3):271-5. PubMed ID: 12628690
[TBL] [Abstract][Full Text] [Related]
19. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Tindall DJ; Rittmaster RS
J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
